Clinical Trial Update: Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing GSK's MMR vaccine to Merck's MMR vaccine in healthy children 12 to 15 months old; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella

Drugs mentioned

• MMR vaccine (GSK) (Measles-Mumps-Rubella vaccine)
• MMR vaccine (Merck) (Measles-Mumps-Rubella vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2018-07-03